Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Stock Information for Natuzzi S.p.A.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Natuzzi S.p.A.

Mesoblast Allogeneic Cell Therapy Products Are Designated 'U.S. Country of Origin' and Not Subject to U.S. Tariffs
First Three Children to Commence Treatment With Ryoncil®
Ryoncil® is Now Available for Purchase in the United States
Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States
Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
Mesoblast Added to S&P/ASX 200 INDEX
Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
Mesoblast Financial Results and Corporate Update Webcast

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.